Literature DB >> 19939863

During pregnancy, recreational drug-using women stop taking ecstasy (3,4-methylenedioxy-N-methylamphetamine) and reduce alcohol consumption, but continue to smoke tobacco and cannabis: initial findings from the Development and Infancy Study.

Derek G Moore1, John D Turner, Andrew C Parrott, Julia E Goodwin, Sarah E Fulton, Meeyoung O Min, Helen C Fox, Fleur M B Braddick, Emma L Axelsson, Stephanie Lynch, Helena Ribeiro, Caroline J Frostick, Lynn T Singer.   

Abstract

While recreational drug use in UK women is prevalent, to date there is little prospective data on patterns of drug use in recreational drug-using women immediately before and during pregnancy. A total of 121 participants from a wide range of backgrounds were recruited to take part in the longitudinal Development and Infancy Study (DAISY) study of prenatal drug use and outcomes. Eighty-six of the women were interviewed prospectively while pregnant and/or soon after their infant was born. Participants reported on use immediately before and during pregnancy and on use over their lifetime. Levels of lifetime drug use of the women recruited were high, with women reporting having used at least four different illegal drugs over their lifetime. Most users of cocaine, 3,4-methylenedioxy-N-methylamphetamine (MDMA) and other stimulants stopped using these by the second trimester and levels of use were low. However, in pregnancy, 64% of the sample continued to use alcohol, 46% tobacco and 48% cannabis. While the level of alcohol use reduced substantially, average tobacco and cannabis levels tended to be sustained at pre-pregnancy levels even into the third trimester (50 cigarettes and/or 11 joints per week). In sum, while the use of 'party drugs' and alcohol seems to reduce, levels of tobacco and cannabis use are likely to be sustained throughout pregnancy. The data provide polydrug profiles that can form the basis for the development of more realistic animal models.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19939863      PMCID: PMC3564500          DOI: 10.1177/0269881109348165

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  28 in total

1.  Exploring the validity of self-reported Ecstasy use among club rave attendees.

Authors:  George S Yacoubian; Eric D Wish
Journal:  J Psychoactive Drugs       Date:  2006-03

2.  Pattern of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self-rated aggression and somatic symptoms.

Authors:  R M Milani; A C Parrott; F Schifano; J J D Turner
Journal:  Hum Psychopharmacol       Date:  2005-06       Impact factor: 1.672

Review 3.  A developmental comparison of the neurobehavioral effects of ecstasy (MDMA).

Authors:  Brian J Piper
Journal:  Neurotoxicol Teratol       Date:  2006-10-20       Impact factor: 3.763

4.  MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.

Authors:  J L Reay; C Hamilton; D O Kennedy; A B Scholey
Journal:  J Psychopharmacol       Date:  2006-05       Impact factor: 4.153

Review 5.  Maternal smoking, drinking or cannabis use during pregnancy and neurobehavioral and cognitive functioning in human offspring.

Authors:  Anja C Huizink; Eduard J H Mulder
Journal:  Neurosci Biobehav Rev       Date:  2005-08-10       Impact factor: 8.989

6.  Effects of maternal drinking and marijuana use on fetal growth and development.

Authors:  R Hingson; J J Alpert; N Day; E Dooling; H Kayne; S Morelock; E Oppenheimer; B Zuckerman
Journal:  Pediatrics       Date:  1982-10       Impact factor: 7.124

7.  Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls.

Authors:  C T J Lamers; A Bechara; M Rizzo; J G Ramaekers
Journal:  J Psychopharmacol       Date:  2006-03       Impact factor: 4.153

Review 8.  MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.

Authors:  Andy C Parrott
Journal:  J Psychopharmacol       Date:  2006-03       Impact factor: 4.153

Review 9.  Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.

Authors:  R Thomasius; P Zapletalova; K Petersen; R Buchert; B Andresen; L Wartberg; B Nebeling; A Schmoldt
Journal:  J Psychopharmacol       Date:  2006-03       Impact factor: 4.153

10.  Diagnostic validity of the drug abuse screening test in the assessment of DSM-III drug disorders.

Authors:  D R Gavin; H E Ross; H A Skinner
Journal:  Br J Addict       Date:  1989-03
View more
  28 in total

1.  Depressive symptoms, substance abuse, and intimate partner violence among pregnant women of diverse ethnicities.

Authors:  Kisha B Holden; Robetta McKenzie; Vikki Pruitt; Katrina Aaron; Stephanie Hall
Journal:  J Health Care Poor Underserved       Date:  2012-02

Review 2.  Cannabis, the pregnant woman and her child: weeding out the myths.

Authors:  S C Jaques; A Kingsbury; P Henshcke; C Chomchai; S Clews; J Falconer; M E Abdel-Latif; J M Feller; J L Oei
Journal:  J Perinatol       Date:  2014-01-23       Impact factor: 2.521

3.  Perinatal substance use: a prospective evaluation of abstinence and relapse.

Authors:  Ariadna Forray; Brian Merry; Haiqun Lin; Jennifer Prah Ruger; Kimberly A Yonkers
Journal:  Drug Alcohol Depend       Date:  2015-03-03       Impact factor: 4.492

4.  Identifying prenatal cannabis exposure and effects of concurrent tobacco exposure on neonatal growth.

Authors:  Teresa R Gray; Rina D Eiden; Kenneth E Leonard; Gerard J Connors; Shannon Shisler; Marilyn A Huestis
Journal:  Clin Chem       Date:  2010-07-13       Impact factor: 8.327

5.  Distinct periods of developmental sensitivity to the effects of 3,4-(±)-methylenedioxymethamphetamine (MDMA) on behaviour and monoamines in rats.

Authors:  Matthew R Skelton; Devon L Graham; Tori L Schaefer; Curtis E Grace; Amanda A Braun; Lindsey N Burns; Robyn M Amos-Kroohs; Michael T Williams; Charles V Vorhees
Journal:  Int J Neuropsychopharmacol       Date:  2011-06-28       Impact factor: 5.176

6.  Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy.

Authors:  Lynn T Singer; Derek G Moore; Sarah Fulton; Julia Goodwin; John J D Turner; Meeyoung O Min; Andrew C Parrott
Journal:  Neurotoxicol Teratol       Date:  2012-03-03       Impact factor: 3.763

Review 7.  Illicit substance use in pregnancy - a review.

Authors:  Katherine Scott; Karin Lust
Journal:  Obstet Med       Date:  2010-09-17

8.  Psychiatric profiles of mothers who take Ecstasy/MDMA during pregnancy: reduced depression 1 year after giving birth and quitting Ecstasy.

Authors:  John J D Turner; Andrew C Parrott; Julia Goodwin; Derek G Moore; Sarah Fulton; Meeyoung O Min; Lynn T Singer
Journal:  J Psychopharmacol       Date:  2013-12-10       Impact factor: 4.153

Review 9.  Substance Use in the Perinatal Period.

Authors:  Ariadna Forray; Dawn Foster
Journal:  Curr Psychiatry Rep       Date:  2015-11       Impact factor: 5.285

10.  One-year outcomes of prenatal exposure to MDMA and other recreational drugs.

Authors:  Lynn T Singer; Derek G Moore; Meeyoung O Min; Julia Goodwin; John J D Turner; Sarah Fulton; Andrew C Parrott
Journal:  Pediatrics       Date:  2012-08-20       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.